Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Voyageur Pharmaceuticals ( (TSE:VM) ) has issued an announcement.
Voyageur Pharmaceuticals has entered a non-binding Memorandum of Understanding with Altillion Inc. to create North America’s first vertically integrated iodine drug supply chain. This collaboration aims to address global iodine supply constraints and position Voyageur as a low-cost manufacturer with full control over quality and supply chain continuity. The strategic plan involves a four-phase rollout, including bench scale testing, pilot production, scaling up iodine production, and full manufacturing. Voyageur is also exploring non-dilutive funding opportunities and government support to expand its U.S. operations, aiming to resolve North America’s dependency on iodine drug imports.
More about Voyageur Pharmaceuticals
Voyageur Pharmaceuticals Ltd. is a Canadian public company focused on developing cost-effective imaging contrast media, particularly in the field of iodine and barium-based pharmaceuticals. The company aims to establish a fully integrated manufacturing platform in North America, addressing strategic vulnerabilities in the iodine drug supply chain.
YTD Price Performance: 166.67%
Average Trading Volume: 119,160
Technical Sentiment Signal: Buy
Current Market Cap: C$39.04M
Find detailed analytics on VM stock on TipRanks’ Stock Analysis page.